In this article, we will look at the 11 Cheap Blue Chip Stocks to Buy According to Analysts.

On February 26, Mike Wilson, Morgan Stanley CIO and chief U.S. equity strategist, appeared on CNBC’s ‘Squawk Box’ to talk about the latest market trends and the state of the economy. His view for the year was that we are going to see a broadening in the market, and that is what’s happening. But he also stated that several things are happening in addition to AI, this early cycle emerging from a rolling recession, which is a big deal. Considerable amounts of money are flowing into these cyclical areas, like energy, because it is a group that’s been left for dead and hasn’t done anything for years. The same thing holds for manufacturing and industrial stocks.

READ ALSO: 11 Best Strong Buy Healthcare Stocks to Invest In and 10 Small-Cap Stocks With Huge Growth Potential. 

Wilson further stated that his broader thesis of early-cycle rolling recovery remains intact and that market internals are supportive, even if the index-level action feels choppy. That said, he opined that near-term volatility is likely to persist.

He further stated that the correction at the index level started last fall, with the index peaking in October, and we are thinking it was related to liquidity constraints. If we look at the dispersion under the surface rate now, the market has basically crashed under the surface, which means that the spread between the top 50 stocks and the bottom 50 year to date is 68%, which is the biggest spread we have seen in 20 years by a wide margin. This is telling us that the market is adjusting internally for these concerns. For Wilson, the correction at the stock level is already 70% to 80% done.

With these trends in view, let’s look at the best cheap blue chip stocks to buy according to analysts.

Our Methodology

We sifted through the Finviz stock screener to compile a list of the best blue-chip stocks with a forward P/E below 15 that analysts were bullish on. We then selected the top 11 most popular among elite hedge funds as of Q3 2025, sourcing the hedge fund data from Insider Monkey’s database. The stocks are ranked in ascending order of hedge fund sentiment.

Note: All data was recorded on February 26.

​Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

11 Cheap Blue Chip Stocks to Buy According to Analysts

11. Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) is one of the best cheap blue chip stocks to buy according to analysts. Novo Nordisk A/S (NYSE:NVO) and Vivtex Corporation announced on February 25 a partnership for the development of next-generation oral biologic medicines for obesity, diabetes, and associated comorbidities. The terms of the agreement entail that Vivtex would license select oral drug-delivery technologies to Novo Nordisk A/S (NYSE:NVO), with Vivtex eligible to receive upfront consideration, research funding, and milestone payments totalling up to $2.1 billion, and tiered royalties on future product sales. Vivtex’s platform combines multiple proprietary gastrointestinal screening assays, drug-delivery technologies, and computational simulation and AI capabilities for the optimization of the oral delivery of biologic medicines.

Management further reported that the primary goal of the collaboration is to allow the oral delivery of biologic drug candidates traditionally limited to injectable administration because of poor absorption in the gastrointestinal tract. The partnership thus brings together Novo Nordisk’s (NYSE:NVO) expertise in peptide and protein therapeutics and Vivtex’s proprietary gastrointestinal screening and formulation platform to identify next-generation oral therapeutics. Novo Nordisk A/S (NYSE:NVO) further reported that following research and formulation selection, it will assume responsibility for regulatory activities, global development, manufacturing, and commercialization of any resulting products.

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.

10. MetLife, Inc. (NYSE:MET)

MetLife, Inc. (NYSE:MET) is one of the best cheap blue chip stocks to buy according to analysts. On February 25, Wells Fargo cut the price target on MetLife, Inc. (NYSE:MET) to $93 from $97 while maintaining an Overweight rating on the shares, telling investors that with guidance from most companies in fiscal Q4, the firm is generally cutting its EPS estimates as guides were in line with or below consensus expectations for most companies. It also stated that it is rolling valuation methodologies to 2027 EPS and rolling out new 2028E EPS estimates for companies.

MetLife, Inc. (NYSE:MET) also received a rating update from Mizuho on February 12, with the firm cutting the price target on the stock to $100 from $102 and reaffirming an Outperform rating on the shares. In another development, Evercore ISI adjusted the price target on MetLife, Inc. (NYSE:MET) on February 11. The firm cut the price target on the stock to $95 from $97, keeping an In Line rating on the shares and telling investors that it adjusted estimates after the company released its quarterly report.

MetLife, Inc. (NYSE:MET) provides insurance and financial services to individual and institutional customers. The company’s operations are divided into the following segments: Group Benefits, Retirement and Income Solutions (RIS), Asia, MetLife Holdings, and Corporate and Other.